1. Allogene's Off-the-Shelf CAR-T Shows Potent MRD Clearance in B-Cell Lymphoma Trial
Allogene Therapeutics' experimental off-the-shelf CAR-T therapy has demonstrated a significant advantage in clearing residual cancer cells in patients with B-cell lymphoma, hitting a key interim goal in a pivotal Phase 3 trial. Preliminary data released Monday show the treatment, cema-cel, achieved minimal residual dis...